Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial

Journal of Clinical Oncology

Volumn 19, Issue 18, 2001, Pages 3808-3816

  Ellis, M J ^a   Coop, A ^a   Singh, B ^a   Mauriac, L ^a   Llombert Cussac, A ^a   Janicke F ^a   Miller, W R ^a   Evans, D B ^a   Dugan, M ^a   Brady, C ^a   Quebe Fehling, E ^a   Borgs, M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; LETROZOLE; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; TAMOXIFEN;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; ECHOMAMMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; ONCOGENE NEU; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035884620     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.18.3808     Document Type: Article

References (29)

1. Preoperative endocrine therapy for older women with breast cancer: Renewed interest in an old idea
2. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
3. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or Arimidex randomized group efficacy and tolerability study
4. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
5. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
6. Aromatase inhibitors and breast cancer
7. Molecular mechanisms of antiestrogen action in breast cancer
8. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
9. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
10. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
11. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy
12. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
13. Elevated serum Her-2/neu predicts decreased response to hormone therapy in metastatic breast cancer
14. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study
15. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer
16. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer
17. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
18. Quantitative immunohistochemical assay for hormonal receptors: Technical aspects and biological significance
19. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
20. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
21. Prognostic and predictive factors in breast cancer by immunohistochemical analysis
22. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
23. Steroid receptors and other prognostic factors in primary breast cancer
24. Progesterone receptors as a prognostic factor in stage II breast cancer
25. Tamoxifen for early breast cancer: An overview of the randomised trials
26. Letrozole (Femara) is a more effective inhibitor of estrogen activity than tamoxifen: Evidence from a randomized phase III trial of 4 months preoperative endocrine therapy for postmenopausal women with primary invasive breast cancer
27. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
28. MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells
29. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of Herceptin (trastuzumab) therapy for breast cancer